Trainings and Resources
93 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/16/2022 (updated 9/14/2022)
Almost two-thirds of people currently incarcerated in the U.S. have a substance use disorder. Many struggle with opioid addiction. Opioids include prescription pain relievers, heroin, and powerful synthetic versions such as fentanyl that are driving record numbers of overdose deaths. Medications used to treat opioid use disorder—also called MOUD—can reduce cravings and symptoms of withdrawal. MOUD include buprenorphine, methadone, and naltrexone. However, few jails and prisons offer these evidence-based treatments. The study tested whether medications to treat opioid use disorder can reduce recidivism
Posted 1/5/2022 (updated 9/14/2022)
The Centers for Disease Control and Prevention (CDC) want greater awareness of adverse childhood experiences (ACEs) and their connection to high rates of overdose and suicide. This week they announced a new training webpage, UrgentRelatedPreventable.org, designed in collaboration with the American Public Health Association to provide background and talking points. The site explains how exposure to certain events and conditions in childhood have lasting effects on health, well-being, and prosperity far into adulthood. See Funding section below for a CDC effort to research the links between ACEs and substance use.
Posted 9/22/2021 (updated 9/14/2022)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice. PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 7/28/2021 (updated 9/14/2022)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 11/30/2021 (updated 8/24/2022)
In June, the U.S. Drug Enforcement Administration (DEA) announced that it would allow all opioid treatment programs to add mobile units to help increase access to medications for opioid use disorder, lifting a 13-year moratorium on new vehicles. As the assistant commissioner for the New Jersey Division of Mental Health and Addiction Services in the Department of Human Services, Valerie Mielke oversees the state’s community public mental health system as well as all substance use prevention, treatment, and recovery support services.
Posted 10/20/2021 (updated 8/24/2022)
Justice-involved populations are disproportionately affected by the opioid and overdose crisis. In fact, people who have been incarcerated are roughly 129 times more likely to experience a fatal overdose in the first two weeks after their release compared to the general public due to reduced tolerance during incarceration.1 Despite the fact that evidence-based medication for opioid use disorder (MOUD) is the standard of care in the community, and has been proven to reduce risk of overdose and mortality, it remains widely unavailable in most correctional facilities. However, that is slowly changing. Correctional staff, medical professionals, incarcerated individuals and politicians are beginning to advocate for MOUD. JPOP aims to address the need for accessible information about medication-based treatment for opioid use disorder in the criminal legal system. We encourage you to engage with the resources and tools and links on this website to help to improve treatment for opioid use disorder in your community
Posted 6/17/2021 (updated 8/17/2022)
Fueled by misinformation, fentanyl panic has harmed public health through complicating overdose rescue while rationalizing hyper-punitive criminal laws, wasteful expenditures, and proposals to curtail vital access to pain pharmacotherapy. To assess misinformation about health risk from casual contact with fentanyl, we characterize its diffusion and excess visibility in mainstream and social media.
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
On March 16, 2020, to facilitate access to methadone treatment from opioid treatment programs (OTPs) during the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration allowed states to request blanket exceptions to provide up to 28 and 14 days of take-home methadone for stable and less stable patients, respectively; this signaled a shift in practice because most patients historically receive methadone daily from OTPs.
Posted 11/25/2020 (updated 7/11/2022)
Jails and prisons are critical intervention points in addressing the nation’s overdose crisis. Many systems, including correctional facilities, are beginning to recognize that access to evidence-based treatment and medication for substance use disorder saves lives and must form a fundamental component of any effective program. This Virtual Event Series will highlight best practices, challenges and opportunities in implementing medication-based treatment in correctional facilities over four sessions.